Form 4 for ABCL AbCellera Biologics Inc.
Accepted 2021-12-09 00:00:00 ET · period of report 2021-12-08 · accession 0001209191-21-068844 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-09 | 2021-12-08 | ABCL | Lecault Veronique | COO, Dir | M - OptEx | $0.19 | +250.0K | 1.59M | +19% | +$47.5K |
| D | 2021-12-09 | 2021-12-08 | ABCL | Lecault Veronique | COO, Dir | M - OptEx | $0.00 | -250.0K | 2.52M | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2021-12-08 | M | A | 250,000 | $0.19 | 1,589,333 | D | — | — | |
| 2 | Derivative | Share Option (right to buy) | 2021-12-08 | M | D | 250,000 | $0.00 | 2,524,134 | D | $0.19 · — to 2027-03-23 | 250,000 Common Shares | (F3) The shares subject to such option vest and become exercisable annually in substantially equal installments over a six-year period, with the first tranche vested on November 8, 2017, subject to the Reporting Person's continuous service to the Issuer on each such date. |